GlassScriptPhysician profile
Mary E Carter
NPI 1316487994
$1,485.45
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $643 · 2022: $301 · 2023: $278 · 2024: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $787.34 | 2021-2024 | |
| Novo Nordisk INC | $144.92 | 2021-2023 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $75.87 | 2021-2023 | Rexulti |
| Esperion Therapeutics, INC. | $59.06 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $55.16 | 2021-2024 | Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $51.68 | 2022 | |
| Pfizer INC. | $45.71 | 2021 | |
| Glaxosmithkline, LLC. | $43.73 | 2022-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $36.14 | 2024 | Evenity, Prolia, Repatha |
| Daiichi Sankyo INC. | $35.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.89 | 2023 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $19.70 | 2021 | |
| Dexcom, INC. | $19.33 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.84 | 2021 | |
| Sandoz INC. | $15.73 | 2023 | Hyrimoz |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $14.73 | 2022 | |
| Abbott Laboratories | $13.89 | 2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $12.50 | 2021 | |
| Lundbeck LLC | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.